Cochlear Limited ((CHEOF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cochlear Limited is conducting a study titled ‘A Post-Market, Prospective, Multi-Centre, Open-Label, Comparative, Interventional Study of Adult Cochlear Implant Speech Performance and Clinic Efficiency With Remote Care Compared With Standard of Care in the First 12 Months Post-initial Activation.’ The study aims to evaluate the effectiveness of Cochlear’s Remote Care solutions, Remote Check and Remote Assist, compared to traditional in-clinic management for adults with cochlear implants. The focus is on assessing speech performance and clinic efficiency, as well as potential cost savings and efficiency gains from remote aftercare.
The study tests two interventions: Cochlear™ Remote Care, which includes Remote Check and Remote Assist, and the standard in-clinic care. Remote Check allows for remote hearing assessments via the Cochlear™ Nucleus® Smart App, while Remote Assist facilitates video call appointments for remote adjustments. These interventions aim to enhance patient care and clinic efficiency.
This interventional study is designed as a randomized, parallel assignment with no masking, focusing on health services research. Participants are randomly allocated to either the experimental group receiving remote care or the active comparator group receiving standard care.
The study began on September 6, 2022, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on September 22, 2025. These dates are crucial for tracking the study’s progress and anticipated outcomes.
The study’s findings could significantly impact Cochlear Limited’s market position by demonstrating the effectiveness and efficiency of remote care solutions, potentially boosting investor confidence and stock performance. This development is particularly relevant in the context of increasing demand for telehealth solutions in the healthcare industry.
The study is ongoing, and further details are available on the ClinicalTrials portal.